In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
The Healthcare Select Sector SPDR ETF’s (XLV) price has increased ~14.6% in the third quarter, and its year-to-date returns increased ~15.5% on October 2.
Leading pharmaceutical company Allergan (AGN), which deals in generic and specialty pharmaceutical products, segregated its business into three segments: US General Medicines, US Specialized Therapeutics, and International.
On January 22, Vermont decriminalized the possession of marijuana for adults 21 and older. Vermont became the ninth state to legalize marijuana for recreational purposes.
In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.
Johnson & Johnson’s (JNJ) gross profit margin decreased to 64.9% during 3Q17, a decline of ~4.0% compared to the gross profit margin of 69.2% during 3Q16.
The oncology portfolio Bristol-Myers Squibb’s (BMY) oncology portfolio includes key products Empliciti, Opdivo, Sprycel, and Yervoy. The oncology portfolio contributes over 40% of Bristol-Myers Squibb’s total revenue. Empliciti The above chart compares key oncology products’ revenue over the last few quarters. Empliciti is the latest drug launched by Bristol-Myers Squibb for the treatment of multiple myeloma. […]
In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals’ (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.
In 3Q17, Eli Lilly’s overall revenues from oncology products fell due to lower sales of Alimta, Erbitux, and Portrazza, offset by a rise in Cyramza sales.
Bridion revenue In 3Q17, Merck’s (MRK) Bridion reported revenue of $185 million, which reflected ~33% growth YoY (year-over-year) and 13% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Bridion generated revenue of $495 million, which reflected 44% growth YoY. Growth in US sales volumes primarily contributed to the drug’s revenue growth in the two […]
Immunology drug revenue In 3Q17, Remicade generated revenue of $214 million, a ~31% fall YoY (year-over-year) and 3% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Remicade reported revenue of $651 million, which reflected a ~35% fall YoY. Foreign exchange had a 3% favorable effect towards 3Q17 Remicade revenue. In 3Q17, Simponi reported revenue of […]
The latest report was released on November 3 and indicated that the goods and services deficit was $43.5 billion in September, or $0.7 billion higher than in August.
On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.
Forteo is used for the treatment of osteoporosis. Forteo’s sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16.
In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.
In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem reported revenues of ~$298 million, which represented a YoY (year-over-year) growth of ~6% and sequential growth of ~9%.
The key products in Bristol-Myers Squibb’s (BMY) oncology portfolio include Empliciti, Opdivo, Sprycel, and Yervoy. Let’s take a closer look at these drugs and their performances.
In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.
A look at Bristol-Myers Squibb Headquartered in New York City, Bristol-Myers Squibb (BMY) is an American pharmaceutical company that develops innovative medicines in various therapeutic areas, including cardiovascular, neuroscience, immunoscience, oncology, and virology. Stock price performance While Bristol-Myers Squibb’s stock price has risen ~3.8% in 2Q17, it had fallen ~5.4% year-to-date as of July 7, […]
Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.
Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.
JNJ’s overall business is classified into three segments: Pharmaceuticals, Consumer, and Medical Devices. At constant exchange rates, the company reported growth across all of its segments.
Bausch & Lomb projections Valeant Pharmaceuticals expects its Bausch & Lomb/International segment to grow at a CAGR (compound average growth rate) of 4%–6% between 2017 and 2020. In 2017, the company expects the segment to grow 5%–7% after adjusting for foreign exchange fluctuations and the impact of impending patent expiries. In 2017, the segment is also expected […]
New product launches Despite upcoming patent expirations for drugs Elidel, Solodyn, and Acanya in 2018, and Zyclara in 2019, Valeant Pharmaceuticals (VRX) expects to boost its dermatology revenue after 2018 through new product launches. On December 12, 2016, the company hired Bill Humpries as executive vice president and head of the dermatology team. The change […]
Gastrointestinal franchise prescriptions In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) drugs Xifaxan, Uceris, Apris, and Relistor reported solid year-over-year (or YoY) growth in prescriptions, of around 18%, 6%, 4%, and 1%, respectively. Relistor growth trends Since the launch of the oral version of Relistor in 4Q16, the drug has witnessed a 13% rise in total […]
Baxter has been actively involved in various research and development initiatives to provide better technology products and services to healthcare providers for better patient care.
Although generic drugs are the same as branded drugs in terms of the medicinal effect, their prices are extremely low compared to the branded products.
Mylan’s 2Q16 revenues were mainly driven by 4% growth at constant exchange rates in its Generics segment, which reported a rise to $2.14 billion in 2Q16.
Mylan’s (MYL) revenues rose 8% at constant exchange rates in 2Q16, reporting revenues of ~$2.6 billion, as compared to its 2Q15 revenues of ~$2.4 billion.
Akorn’s (AKRX) robust research and development pipeline is comprised of branded and generic drugs with a total addressable market value of about $9.2 billion.
Keytruda, a prescription medicine classified under Merck and Co.’s (MRK) Immuno-oncology franchise, is used to treat non-small cell lung cancer as well as melanoma.
TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]
In 2016, Biogen (BIIB) expects strong growth in demand for Eloctate, its hemophilia drug. Eloctate is expected to be adopted by more hemophilia patients who require long-acting therapies.
Aside from the risky generic pharmaceutical industry, Mylan faces company-specific business risks like country risk, foreign exchange risk, and M&A risk.
